BI-770371

Boehringer Ingelheim's SIRP inhibitor BI 765063, when combined with PD-1 inhibitor ezabenlimab and cetuximab, showed manageable safety and promising antitumor activity in patients with recurrent/metastatic head and neck cancer.

Boehringer Ingelheim reached 66 million patients in 2024, an 8% increase from the previous year, while investing €6.2 billion (23.2% of net sales) in research and development.

OSE Immunotherapeutics reported total income of €83.4 million for 2024, with a cash position of €64.2 million ensuring financial visibility until Q1 2027.

OSE Immunotherapeutics reported total H1 2024 incomes of €82.5 million, driven by new partnerships with AbbVie and Boehringer Ingelheim, strengthening its financial position.

OSE Immunotherapeutics initiates the Artemia Phase 3 trial to evaluate Tedopi® in second-line metastatic non-small cell lung cancer (NSCLC).